NCT05054751 2024-10-10
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Genor Biopharma Co., Ltd.
Phase 3 Completed
Clinical Trials
8 trialsNCT04500587 2024-09-19
Phase 1 First in Human Study of ZN-d5 as a Single Agent
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1 Completed
NCT05199337 2024-09-19
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02762084 2020-07-23
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
PellePharm, Inc.
Phase 2 Completed
NCT03236974 2020-02-06
D6090C00002
AstraZeneca
Phase 1 Completed
NCT01403610 2019-07-24
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT02828111 2019-01-08
BCC
PellePharm, Inc.
Phase 2 Completed
NCT00582660 2017-06-15
UAB0040
University of Alabama at Birmingham
Phase 2 Completed